Tuesday, 02 January 2024 12:17 GMT

The Power Of Prevention: Detecting Diabetes Before It Strikes


(MENAFN- PR Newswire)

SAN DIEGO, Nov. 20, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL ), a global leader in in vitro diagnostics, has released Episode 53 of its Science Bytes podcast, featuring Qian Ding, MD, PhD, Senior Medical Affairs Manager, QuidelOrtho, an expert in clinical and laboratory medicine with deep experience in healthcare information systems and data analytics.

Continue Reading



Episode 53: QuidelOrtho Science Bytes


Qian Ding, MD, PhD, Senior Medical Affairs Manager, QuidelOrtho

In the episode titled "Don't Wait for the Wake-Up Call, " Dr. Ding explains why early detection of diabetes is a clinical and economic priority. With diabetes affecting millions of people worldwide – many undiagnosed until complications arise – early testing offers a critical opportunity to shift care from reactive to proactive. Dr. Ding shares how modern laboratory platforms and emerging biomarkers are helping clinicians intervene sooner, personalize care and prevent long-term harm.

Key insights include:

  • Early action saves lives: Detecting diabetes before complications occur changes the patient's health trajectory.
  • Beyond glucose: Emerging biomarkers like C-peptide, pro-insulin and adiponectin offer a more complete metabolic picture.
  • Smarter labs, faster answers: Automation-ready platforms deliver reliable results quickly, supporting timely clinical decisions.
  • Economic impact: Early testing reduces costly interventions and aligns with value-based care models.
  • Equity in care: Tailored testing strategies ensure accurate diagnosis across diverse populations.

This episode underscores how collaboration between labs and clinicians can help close the loop between diagnostics and care – empowering better outcomes and healthier futures.

The QuidelOrtho Science Bytes podcast is available on major streaming platforms and at: .

About QuidelOrtho Corporation

With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL ) is a leading global provider of diagnostic solutions, delivering fast, accurate and reliable results that help improve patient outcomes – from the point of care to lab, clinic to hospital. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.

Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
[email protected]

Media Contact:
D. Nikki Wheeler
Senior Director, Corporate Communications
[email protected]

SOURCE QuidelOrtho Corporation

21% more press release views with Request a Demo

MENAFN20112025003732001241ID1110373862



PR Newswire

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Search